Evaluation of the toxicological effects of favipiravir (T-705) on liver and kidney in rats : biochemical and histopathological approach
Favipiravir is a selective RNA polymerase inhibitor and a broad-spectrum antiviral drug, an important agent used in viral infections, including Ebola, Lassa, and COVID-19. This study aims to evaluate the potential toxicological effects of favipiravir administration on rats' liver and kidney tissues. Favipiravir was applied for five and ten days in the present study. During this period, it was aimed to determine possible toxic effects on the liver and kidney. For this purpose, the impact of favipiravir on liver and kidney tissues were examined using histopathologic and biochemical methods. The present study showed that favipiravir administration led to an elevation in the liver and kidney serum enzymes and oxidative and histopathologic damages. Favipiravir administration caused apoptotic cell death (Caspase-3 and Bcl-2), inflammation (NF-κB and IL-6), and a decrease in renal reabsorption (AQP2) levels. In the evaluation of the findings obtained in this study, it was determined that the favipiravir or metabolites caused liver and kidney damages.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:46 |
|---|---|
| Enthalten in: |
Drug and chemical toxicology - 46(2023), 3 vom: 21. Mai, Seite 546-556 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kara, Adem [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Amides |
|---|
| Anmerkungen: |
Date Completed 21.03.2023 Date Revised 21.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/01480545.2022.2066116 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339797258 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339797258 | ||
| 003 | DE-627 | ||
| 005 | 20231226003710.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/01480545.2022.2066116 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1132.xml |
| 035 | |a (DE-627)NLM339797258 | ||
| 035 | |a (NLM)35450509 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kara, Adem |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of the toxicological effects of favipiravir (T-705) on liver and kidney in rats |b biochemical and histopathological approach |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.03.2023 | ||
| 500 | |a Date Revised 21.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Favipiravir is a selective RNA polymerase inhibitor and a broad-spectrum antiviral drug, an important agent used in viral infections, including Ebola, Lassa, and COVID-19. This study aims to evaluate the potential toxicological effects of favipiravir administration on rats' liver and kidney tissues. Favipiravir was applied for five and ten days in the present study. During this period, it was aimed to determine possible toxic effects on the liver and kidney. For this purpose, the impact of favipiravir on liver and kidney tissues were examined using histopathologic and biochemical methods. The present study showed that favipiravir administration led to an elevation in the liver and kidney serum enzymes and oxidative and histopathologic damages. Favipiravir administration caused apoptotic cell death (Caspase-3 and Bcl-2), inflammation (NF-κB and IL-6), and a decrease in renal reabsorption (AQP2) levels. In the evaluation of the findings obtained in this study, it was determined that the favipiravir or metabolites caused liver and kidney damages | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Favipiravir | |
| 650 | 4 | |a kidney | |
| 650 | 4 | |a liver | |
| 650 | 4 | |a rats | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Aquaporin 2 |2 NLM | |
| 650 | 7 | |a favipiravir |2 NLM | |
| 650 | 7 | |a EW5GL2X7E0 |2 NLM | |
| 650 | 7 | |a Amides |2 NLM | |
| 650 | 7 | |a Pyrazines |2 NLM | |
| 700 | 1 | |a Yakut, Seda |e verfasserin |4 aut | |
| 700 | 1 | |a Caglayan, Cuneyt |e verfasserin |4 aut | |
| 700 | 1 | |a Atçalı, Tuğçe |e verfasserin |4 aut | |
| 700 | 1 | |a Ulucan, Aykut |e verfasserin |4 aut | |
| 700 | 1 | |a Kandemir, Fatih Mehmet |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug and chemical toxicology |d 1984 |g 46(2023), 3 vom: 21. Mai, Seite 546-556 |w (DE-627)NLM000913685 |x 1525-6014 |7 nnns |
| 773 | 1 | 8 | |g volume:46 |g year:2023 |g number:3 |g day:21 |g month:05 |g pages:546-556 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/01480545.2022.2066116 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 46 |j 2023 |e 3 |b 21 |c 05 |h 546-556 | ||